Verrica Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $-1,781 | $5,177 | $3,826 | $1,988 |
Gross Profit | -2,216 | 4,635 | 2,688 | 1,607 |
EBITDA | -20,142 | -14,484 | -17,672 | -22,092 |
EBIT | -20,484 | -14,818 | -18,012 | -22,309 |
Net Income | -22,860 | -17,186 | -20,331 | -24,614 |
Net Change In Cash | -1,781 | 5,177 | 3,826 | 1,988 |
Free Cash Flow | -8,574 | -16,369 | -19,947 | -14,958 |
Cash | 22,959 | 31,930 | 48,939 | 69,547 |
Basic Shares | 46,805 | 46,502 | 46,483 | 46,311 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $5,124 | $9,032 | $12,000 | $12,000 |
Gross Profit | 4,378 | 8,307 | 11,528 | -229 |
EBITDA | -62,197 | -21,597 | -30,313 | -39,432 |
EBIT | -63,033 | -22,315 | -30,785 | -39,661 |
Net Income | -66,995 | -27,678 | -38,903 | -45,497 |
Net Change In Cash | 5,124 | 9,032 | 12,000 | 12,000 |
Cost of Revenue | 18,521 | 5,066 | 1,445 | |
Free Cash Flow | -38,939 | -18,952 | -28,465 | -31,677 |
Cash | 69,547 | 34,273 | 15,752 | 10,686 |
Basic Shares | 45,342 | 34,163 | 27,044 | 24,995 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.49 |
2024-06-30 | -$0.37 |
2024-03-31 | -$0.44 |
2023-12-31 | -$0.53 |
